BAR-BUPRENORPHINE 20 MCG
BUPRENORPHINE : 20 MCG · DIN 02493632 · BARD PHARMACEUTICALS (1990) INC
Health Canada status: CANCELLED PRE MARKET
What is BAR-BUPRENORPHINE?
BAR-BUPRENORPHINE 20 MCG contains BUPRENORPHINE : 20 MCG. It is listed in the Health Canada Drug Product Database under DIN 02493632, held by BARD PHARMACEUTICALS (1990) INC, supplied as PATCH for TRANSDERMAL administration. Health Canada currently lists it as cancelled pre market, status dated 15-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BAR-BUPRENORPHINE used for?
Management of pain severe enough to require daily, continuous, long-term opioid treatment, that is opioid-responsive and for which alternative options are inadequate. Not for as-needed use.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02493632 |
|---|---|
| Brand name | BAR-BUPRENORPHINE |
| Generic / active ingredient | BUPRENORPHINE : 20 MCG |
| Manufacturer | BARD PHARMACEUTICALS (1990) INC |
| Strength | 20 MCG |
| Dosage form | PATCH |
| Route of administration | TRANSDERMAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AE01 BUPRENORPHINE |
| AHFS class | 28:08.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 15-Apr-2024 |
How is it administered?
For transdermal use on intact skin only. Apply to a non-irritated site and wear for 7 days. Opioid-naïve patients should start with the 5 mcg/h patch. Titrate based on individual response.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. (Inferred from standard Canadian monograph sections, though specific text was truncated, the summary table and general opioid storage apply).
How is it supplied?
Available in four strengths: 5, 10, 15, and 20 mcg/h. (Specific container details like bottle/box count not provided in text snippet).
Contraindications
Hypersensitivity to buprenorphine/opioids; ileus; suspected surgical abdomen; acute pain/peri-operative use; severe respiratory depression/asthma; acute alcoholism; severe CNS depression; MAOIs use.
Warnings and precautions
Serious risks of addiction, abuse, misuse, and life-threatening respiratory depression. Accidental exposure can be fatal. Avoid external heat sources at the patch site. Risk of hypotension.
What can be used instead?
Other Canadian products sharing ATC code N02AE01 BUPRENORPHINE. 4 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUTRANS 10 | 10 MCG | PATCH | PURDUE PHARMA | MARKETED | DIN 02341212 |
| BUTRANS 15 | 15 MCG | PATCH | PURDUE PHARMA | MARKETED | DIN 02450771 |
| BUTRANS 20 | 20 MCG | PATCH | PURDUE PHARMA | MARKETED | DIN 02341220 |
| BUTRANS 5 | 5 MCG | PATCH | PURDUE PHARMA | MARKETED | DIN 02341174 |
| BAR-BUPRENORPHINE | 10 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | DIN 02493616 |
| BAR-BUPRENORPHINE | 15 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | DIN 02493624 |
| BAR-BUPRENORPHINE | 5 MCG | PATCH | BARD PHARMACEUTICALS (1990) INC | CANCELLED PRE MARKET | DIN 02493608 |
| BELBUCA | 150 MCG | FILM, SOLUBLE | PURDUE PHARMA | CANCELLED POST MARKET | DIN 02465248 |
| BELBUCA | 300 MCG | FILM, SOLUBLE | PURDUE PHARMA | CANCELLED POST MARKET | DIN 02465256 |
| BELBUCA | 450 MCG | FILM, SOLUBLE | PURDUE PHARMA | CANCELLED POST MARKET | DIN 02465264 |
Who else supplies BUPRENORPHINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUPRENORPHINE appears in 392 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.